Radiopharmaceutical developer Actithera closed a $75.5 million Series A financing round to advance clinical development of small-molecule therapeutics targeting fibroblast activation protein (FAP). Despite operating as a solo founder company during the fundraising, CEO Andreas Goutopoulos leveraged his 25+ years of pharma industry experience and strong academic collaborations to attract investor confidence. Actithera plans to enter the clinic and build out its leadership team, aiming to capitalize on growing investor interest in radio-ligand therapies, which deliver tumor-specific radiation via molecular targeting.